| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)
CYCC Technical Analysis
5
| As on 9th Jun 2023 CYCC SHARE Price closed @ 0.67 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.06 & Strong Sell for SHORT-TERM with Stoploss of 3.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CYCCSHARE Price
| Open | 0.67 | Change | Price | % |
| High | 0.68 | 1 Day | -0.01 | -1.47 |
| Low | 0.65 | 1 Week | 0.03 | 4.69 |
| Close | 0.67 | 1 Month | 0.09 | 15.52 |
| Volume | 19921 | 1 Year | -2.96 | -81.54 |
| 52 Week High 4.45 | 52 Week Low 0.52 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CYCC Daily Charts |
CYCC Intraday Charts |
Whats New @ Bazaartrend |
CYCC Free Analysis |
|
|
CYCC Important Levels Intraday
| RESISTANCE | 0.73 |
| RESISTANCE | 0.71 |
| RESISTANCE | 0.70 |
| RESISTANCE | 0.69 |
| SUPPORT | 0.65 |
| SUPPORT | 0.64 |
| SUPPORT | 0.63 |
| SUPPORT | 0.61 |
CYCC Forecast April 2024
| 4th UP Forecast | 3.04 |
| 3rd UP Forecast | 2.28 |
| 2nd UP Forecast | 1.81 |
| 1st UP Forecast | 1.34 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | -0.47 |
| 3rd DOWN Forecast | -0.94 |
| 4th DOWN Forecast | -1.7 |
CYCC Weekly Forecast
| 4th UP Forecast | 2.33 |
| 3rd UP Forecast | 1.80 |
| 2nd UP Forecast | 1.47 |
| 1st UP Forecast | 1.14 |
| 1st DOWN Forecast | 0.20 |
| 2nd DOWN Forecast | -0.13 |
| 3rd DOWN Forecast | -0.46 |
| 4th DOWN Forecast | -0.99 |
CYCC Forecast2024
| 4th UP Forecast | 8.44 |
| 3rd UP Forecast | 5.95 |
| 2nd UP Forecast | 4.41 |
| 1st UP Forecast | 2.87 |
| 1st DOWN Forecast | -1.53 |
| 2nd DOWN Forecast | -3.07 |
| 3rd DOWN Forecast | -4.61 |
| 4th DOWN Forecast | -7.1 |
Cyclacel Pharmaceuticals Inc ( NASDAQ USA Symbol : CYCC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CYCC Business Profile
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. Address: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service